

Reference:	FOI.18300.25
Subject:	Intra-vitreous injections or implants
Date of Request:	8 September 2025

Requested:

- How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from May to August 2025:
 - Aflibercept
 - Bevacizumab
 - Brolucizumab
 - Dexamethasone
 - Faricimab
 - Fluocinolone acetonide
 - Ranibizumab - Lucentis
 - Ranibizumab - Biosimilar
- Please provide the number of injections/implants by eye condition for the four-month period from May to August 2025:

Number of Injections/Implants: May to August 2025:

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept			
Bevacizumab			
Dexamethasone			
Faricimab			
Ranibizumab - Lucentis			
Ranibizumab - Ongavia (Ongavia, Ximluci, Byooviz, Rimmyrah)			

Response:

- Hywel Dda University Health Board (UHB) provides within the table below, the number of each of the listed intravitreal injections/implants administered, during the period 1 May to 31 August 2025.

Medication	Number
Aflibercept	661
Bevacizumab	2
Brolucizumab	0
Dexamethasone	132
Faricimab	1,454
Fluocinolone acetonide	0
Ranibizumab - Lucentis	0
Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)	1,323

2. The UHB provides within the table below, the number of each of the listed intravitreal injections/implants administered, by eye condition, during the period 1 May to 31 August 2025.

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	359	139	163
Bevacizumab	2	0	0
Dexamethasone	2	55	75
Faricimab	1006	230	218
Ranibizumab - Lucentis	0	0	0
Ranibizumab – Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)	887	205	231